S
OREX

SignatureFD’s Orexigen Therapeutics, Inc. OREX Stock Holding History

SignatureFD’s Portfolio OREX Stock Details OREX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-200
Closed -$1K – 1586
2016
Q3 		$1K Buy
+200
New +$755 ﹤0.01% 1573

Other funds holding OREX

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
FCMI
Foresite Capital Management II Larkspur, California $29.2M AUM 44.84% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
FCMI
Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
OWIM
Old West Investment Management Los Angeles, California $923M AUM 112.31% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

SignatureFD's OREX Position: Q4 2016 in Review

SignatureFD sold out of Orexigen Therapeutics, Inc. (OREX) in Q4 2016, closing a stake of 200 shares — an estimated $1K sold.

SignatureFD first reported a position in OREX in Q3 2016 and held it in 1 quarter. The position peaked at $1K in Q3 2016. 53 funds tracked by Wall St. Rank hold OREX as of Q4 2016.

  • SignatureFD reported no remaining Orexigen Therapeutics, Inc. position as of Q4 2016 after selling out during the quarter.
  • SignatureFD sold 200 Orexigen Therapeutics, Inc. shares in Q4 2016, an estimated $1K.
  • SignatureFD first reported a position in Orexigen Therapeutics, Inc. in Q3 2016 and held it in 1 quarter.
  • SignatureFD's Orexigen Therapeutics, Inc. position peaked at $1K in Q3 2016.
  • 53 funds tracked by Wall St. Rank held Orexigen Therapeutics, Inc. as of Q4 2016.

Based on SignatureFD's 13F filing for Q4 2016, filed 14 Feb 2017.